tralokinumab · Adbry
Monoclonal antibody
Evidence outlook
Approved: Atopic Dermatitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments
- ADTRALZA (tralokinumab injection) is indicated for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADTRALZA can be used with or without topical corticosteroids.
- Adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
Development in Asthma stopped (2018-01) for reasons the sponsor has not stated. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ADHAND NCT05958407 · Atopic Dermatitis, Atopic Hand Eczema The 235 participants were randomized 2:1 to tralokinumab or placebo and the initial 16-week comparison was double-blinded. The primary clinical endpoint—an Investigator’s Global Assessment score of 0 or 1 at Week 16—was met, occurring in 40.0% of the tralokinumab group versus 10.6% of the placebo group (p<.001). Registry: NCT05958407 | 3 | Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16) 2025-05-05 | Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9) | Reliable signal | link ↗ |
View 4 more trials
ECZTRA 1 NCT03131648 · Atopic Dermatitis This was a randomized, double-blind, placebo-controlled phase 3 trial of 802 adults that met both of its primary endpoints at week 16 (IGA 0/1: 15.8% vs 7.1%, p=0.002; EASI75: 25.0% vs 12.7%, p<0.001). A power calculation for the primary endpoint was reported in the protocol, and the trial enrolled 802 of a planned 780. Registry: NCT03131648 | 3 | Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16; Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16 2018-08-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
ECZTRA 2 NCT03160885 · Atopic Dermatitis This was a randomized, double-blind, placebo-controlled phase 3 trial of 794 adults that met both of its primary endpoints at week 16 (IGA 0/1: 22.2% vs 10.9%; EASI75: 33.2% vs 11.4%; both p<0.001). A power calculation for the primary endpoint was reported in the protocol, and the trial enrolled 794 of a planned 780. Registry: NCT03160885 | 3 | Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16.; Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI]. (At Week 16) 2018-09-04 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT03363854 NCT03363854 · Atopic Dermatitis This was a randomized, double-blind, placebo-controlled phase 3 trial of 380 adults, with topical steroids allowed in both arms, that met both primary endpoints at week 16 (IGA 0/1: 98 of 252 vs 33 of 126, p=0.015; EASI75: 141 of 252 vs 45 of 126, p<0.001). A power calculation for the primary endpoint was reported in the protocol, and the trial enrolled 380 of a planned 369. Registry: NCT03363854 | 3 | Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16; Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16 2019-03-08 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT03526861 NCT03526861 · Atopic Dermatitis This was a randomized, double-blind, placebo-controlled phase 3 trial in 301 adolescents in which both tralokinumab doses beat placebo on both primary endpoints at week 16 (IGA 0/1: 17.5% and 21.4% vs 4.3%; EASI75: 27.8% and 28.6% vs 6.4%; all p=0.002 or lower). A power calculation for the primary endpoint was reported in the protocol, and the trial randomized 301 of a planned 294. Registry: NCT03526861 | 3 | Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16; Subjects With at Least 75% Reduction in Eczema Area and Severity Index (EASI75) at Week 16 2020-04-15 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Competitive landscape
Other IL-13 drugs
lebrikizumab, Zumilokibart, REGN20423. Compare all 4 IL-13 drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Atopic Dermatitis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tralokinumab (Adbry): this drug | Approved | Monoclonal antibody | IL-13 | Reliable signal | NCT05958407: Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9) | |
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | Reliable signal | NCT04345367: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30) NCT03349060: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12 (Baseline, Week 12): PF-04965842 100 mg 23.7% | PF-04965842 200 mg 43.8% vs Placebo 7.9% | |
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | Reliable signal | NCT02118766: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4% NCT02118792: Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29 (Day 29): AN2728 Ointment, 2 Percent (%) 31.4% vs AN2728 Ointment, Vehicle 18% | |
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | Partial signal | NCT03908970: Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36) NCT03911401: IGA success (score 0 or 1 with at least a 2-grade improvement) at week 4: difamilast 0.3% 44.6% and 1% 47.1% vs vehicle 18.1%; p<0.001 for each dose vs vehicle. n=83, 85, 83 (Saeki 2022, Br J Dermatol). | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | Weak signal | NCT04417894: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7% NCT03345914: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 (Week 16): Dupilumab 300 mg Q4W + TCS 32.8% | Dupilumab 100 mg or 200 mg Q2W + TCS 29.5% vs Placebo + TCS 11.4% | |
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | Reliable signal | NCT04178967: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9) NCT04146363: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 43.1% (95% CI 37.1 to 49) vs Placebo 12.7% (95% CI 7 to 18.5) | |
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | Reliable signal | NCT03989349: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 37.7% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 26% NCT03985943: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 35.6% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 24.6% | |
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | Reliable signal | NCT06631170: Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001) NCT04773600: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 (Week 4): Roflumilast Cream 0.15% 28.9% vs Vehicle Cream 12% | |
| Ruxolitinib (Opzelura) | Approved | Small molecule | JAK1/2 | Reliable signal | NCT03745638: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5) NCT03745651: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 39% (95% CI 32.6 to 45.6) | VC Period: Ruxolitinib 1.5% Cream BID 51.3% (95% CI 44.6 to 58) vs VC Period: Vehicle Cream BID 7.6% (95% CI 3.5 to 14) | |
| Tapinarof | Approved | Small molecule | Aryl hydrocarbon receptor, Aryl Hydrocarbon Receptor Agonist | Reliable signal | NCT05014568: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 45.4% vs Vehicle Cream 13.9% NCT05032859: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 46.4% vs Vehicle Cream 18% | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03607422: EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). NCT03569293: EASI-75 at week 16 (Measure Up 1): 70% (196/281) upadacitinib 15mg, 80% (227/285) upadacitinib 30mg, vs 16% (46/281) placebo; adjusted difference vs placebo 53.3% [46.4-60.2] and 63.4% [57.1-69.8] respectively, both p<0.0001 | |
| ADSTEM | Phase 3 | Cell therapy | autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Asivatrep | Phase 3 | Small molecule | TRPV1 | Reliable signal | NCT02965118: IGA success (score 0 or 1) at week 8: 36.0% asivatrep vs 12.8% vehicle (P<.001) | |
| Baricitinib (Olumiant) | Phase 3 | Small molecule | JAK, JAK1/2 | Reliable signal | NCT03334422: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5% NCT03334396: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) (16 Weeks): 2 mg Baricitinib 11.4% | 4 mg Baricitinib 16.8% vs Placebo 4.8% | |
| GS101 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Jaktinib (Zepuping) | Phase 3 | Small molecule | JAK1/2/3 | Partial signal | No reviewed efficacy summary in this indication | |
| LW402 | Phase 3 | Small molecule | JAK1 | Partial signal | No reviewed efficacy summary in this indication | |
| Manfidokimab | Phase 3 | Monoclonal antibody | IL-4R-alpha | Partial signal | No reviewed efficacy summary in this indication | |
| Pumecitinib | Phase 3 | Small molecule | JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| QL2108 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| QLM3003 | Phase 3 | Small molecule | JAK | Partial signal | No reviewed efficacy summary in this indication | |
| Rademikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | Partial signal | NCT05017480: vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026). | |
| Rezpegaldesleukin | Phase 3 | Protein / enzyme therapeutic | IL-2 mutein (Treg-selective) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1819 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Soficitinib (ICP-332) | Phase 3 | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| SSGJ-611 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Stapokibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | Reliable signal | NCT06277765: EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001) NCT05265923: EASI-75 response at week 16: 66.9% stapokibart vs 25.8% placebo (significantly higher) | |
| Telikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Tilrekimig | Phase 3 | Multispecific antibody | IL-4/IL-13/TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| VC005 | Phase 3 | Small molecule | JAK1, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Zemprocitinib | Phase 3 | Small molecule | JAK1 | Reliable signal | NCT06277245: EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001) | |
| Afimkibart | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| AK139 | Phase 2 | Multispecific antibody | IL-4 receptor alpha / ST2 | not yet graded | No reviewed efficacy summary in this indication | |
| Barzolvolimab | Phase 2 | Monoclonal antibody | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| Bempikibart | Phase 2 | Monoclonal antibody | IL-7 receptor alpha | not yet graded | No reviewed efficacy summary in this indication | |
| BFB759 | Phase 2 | Monoclonal antibody | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| Bosakitug | Phase 2 | Monoclonal antibody | TSLP | Weak signal | NCT05932654: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 (Week 26): 300 mg 94.1% (95% CI 71.3 to 99.9) | |
| Camoteskimab | Phase 2 | Monoclonal antibody | IL-18 | Partial signal | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | Weak signal | Featured results are safety only in this race | |
| CMS-D001 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| ENV-294 | Phase 2 | Small molecule | — | Weak signal | Featured results are safety only in this race | |
| EVO101 | Phase 2 | Small molecule | IRAK4 | Partial signal | NCT05579899: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): EVO101 Cream -43.5% (Standard Deviation 60.85) vs Vehicle Cream -62% (Standard Deviation 38.78) missed | |
| EVO301 | Phase 2 | Protein / enzyme therapeutic | IL-18 | Partial signal | NCT06723405: Placebo-adjusted improvement in EASI at Week 12: 33% (95% CI -50, -17; p<0.01) | |
| FB825 | Phase 2 | Monoclonal antibody | CεmX domain of membrane-bound IgE (mIgE) | Weak signal | No reviewed efficacy summary in this indication | |
| Felcorekibart | Phase 2 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Galvokimig | Phase 2 | Multispecific antibody | IL-13, IL-17A, IL-17F | Partial signal | Featured results are safety only in this race | |
| GHZ339 | Phase 2 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| GIA632 | Phase 2 | Monoclonal antibody | IL-15 | not yet graded | No reviewed efficacy summary in this indication | |
| HSK44459 | Phase 2 | Small molecule | PDE4B | not yet graded | No reviewed efficacy summary in this indication | |
| HY209gel | Phase 2 | Small molecule | GPCR19 / GPBAR1 (TGR5, bile acid receptor) | Partial signal | Featured results are safety only in this race | |
| IN-115314 | Phase 2 | Small molecule | JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-95597528 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| JYP0061 | Phase 2 | Small molecule | JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| KT-621 | Phase 2 | Small molecule | STAT6 | Weak signal | Featured results are safety only in this race | |
| Lepzacitinib | Phase 2 | Small molecule | JAK1/JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| LNK01004 | Phase 2 | Small molecule | Pan-JAK | Partial signal | Featured results are safety only in this race | |
| LT-002-158 | Phase 2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Lunsekimig | Phase 2 | Antibody-derived scaffold | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| Lutikizumab | Phase 2 | Multispecific antibody | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Modzatinib | Phase 2 | Small molecule | ITK and JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| Mosedipimod | Phase 2 | Small molecule | NF-kB / CCL26 pathway | not yet graded | No reviewed efficacy summary in this indication | |
| Nitrosomonas Eutropha (B244) | Phase 2 | Microbiome therapeutic | live biotherapeutic (topical ammonia-oxidizing bacterium, AOBiome/B244) | Reliable signal | NCT04490109: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) (Baseline to Day 28): B244 O.D. 5.0 -2.8 score on a scale (Standard Error 0.184) | B244 O.D. 20.0 -2.8 score on a scale (Standard Error 0.184) vs Vehicle -2.1 score on a scale (Standard Error 0.18) | |
| Zumilokibart | Phase 2 | Monoclonal antibody | IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| REGN20423 | Phase 1 | Monoclonal antibody | IL-13 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 63 furthest-along competitors are listed; 49 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Adbry (tralokinumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2030 (1)
June 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent